Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 10 (Search time: 0.004 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2013Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2Eadie, L.; Saunders, V.; Hughes, T.; White, D.
2013Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapyAngelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G.
2013Which TKI? An embarrassment of riches for chronic myeloid leukemia patientsHughes, T.; White, D.
2013Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagySchafranek, L.; Leclercq, T.; White, D.; Hughes, T.
2013STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent mannerSchafranek, L.; Nievergall, E.; Powell, J.; Hiwase, D.; White, D.; Hughes, T.; Leclercq, T.
2013Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cellsHiwase, D.; Saunders, V.; Nievergall, E.; Ross, D.; White, D.; Hughes, T.
2013Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cellsWhite, D.; Eadie, L.; Saunders, V.; Hiwase, D.; Hughes, T.
2013Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformationKok, C.; Watkins, D.; Leclercq, T.; D'Andrea, R.; Hughes, T.; White, D.
2013NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisisWatkins, D.; Hughes, T.; White, D.; D'Andrea, R.
2013Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.